【阿斯利康将以高达10亿美元的价格收购EsoBiotec】金十数据3月17日讯,英国生物制药公司阿斯利康周一宣布,它以高达10亿美元的现金收购生物技术公司EsoBiotec SA达成了一项最终协议。EsoBiotec首席执行官Jean-Pierre Latere表示,期待与阿斯利康合作,推进共同目标,为全球更多患者带来具有成本效益的变革性细胞疗法。交易完成后,EsoBiotec将成为阿斯利康的全资子公司,在比利时运营。该交易预计将于2025年第二季度完成,等待监管部门的批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.